Kodiak Sciences Selects Advarra for IRB Services and Technology Partner for Ophthalmology Clinical Trials

Columbia, MD — Advarra, the market leader in regulatory review solutions and clinical research technology for sites and sponsors, today announced Kodiak Sciences Inc. (Nasdaq: KOD) selected Advarra for institutional review board (IRB) services. Kodiak Sciences is a biopharmaceutical company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. Kodiak will utilize Advarra’s expertise in IRB services and clinical research technology to support its clinical trials in ophthalmology.

“Kodiak’s primary objective is to conduct successful studies while ensuring protocol safety, and partnering with Advarra will enable us to focus on the well-being of our study participants knowing compliance and safety are covered,” said Wendy Ko, director of clinical operations at Kodiak Sciences. “Advarra’s dedication to quality and efficiency aligns well with our long-term goals of safeguarding participant protections and our mission to deliver novel retinal treatments to those in need.”

Kodiak had struggled with inefficient solutions that were difficult to use. The company sought an easy-to-use, technology-enabled service that would drive efficiencies in the notoriously time-consuming study startup process as well as help ensure compliance. Advarra, trusted by the top 50 global biopharma sponsors, the top 20 CROs and 50,000 site investigators worldwide, fit the bill. Kodiak chose Advarra based on previous positive experiences with efficiency gains and knowledgeable reviewers coupled with an appreciation of the intuitiveness of its Center for IRB Intelligence (CIRBI) platform.

“Advarra’s CIRBI platform offers an easy-to-navigate portal that provides cumulative reports and notifications, delivering a clear advantage over competitors,” added Ko. “Advarra enables us to streamline processes and concentrate on delivering innovative treatments to patients.”

“Our team is thrilled that Kodiak Sciences has selected Advarra as its IRB of record to support the company’s important research in ophthalmology,” said Lauri Carlile, Executive Vice President, Global Delivery at Advarra. “The collaboration not only demonstrates the value of Advarra’s CIRBI platform but also underscores our leadership in research oversight and advanced clinical trial management tools, all aimed at optimizing study efficiency, and helping ensure compliance. We look forward to a successful partnership with Kodiak.”

Additional Information

• Learn more about Advarra’s IRB services:https://www.advarra.com/review-services/
• Connect with Advarra on LinkedIn:com/company/advarra

About Advarra

Advarra breaks the silos that impede clinical research, aligning patients, sites, sponsors, and CROs in a connected ecosystem to accelerate trials. Advarra is number one in research review services, site and sponsor technology, and clinical trial experience software, and is trusted by the top 50 global biopharma sponsors, top 20 CROs, and over 50,000 site investigators worldwide. Advarra solutions enable collaboration, transparency, and speed needed to optimize trial operations, ensure patient safety and engagement, and reimagine clinical research while improving compliance. For more information, visit advarra.com.

Back to Resources